Breaking news

Flo Health Secures $200M Investment From General Atlantic, Signaling A New Era In Femtech

by THEFUTURE.TEAM

July 31, 2024

In a landmark move for the femtech industry, Flo Health has secured a $200 million investment from General Atlantic, a leading global growth equity firm. This significant capital infusion marks a pivotal moment for the company, underscoring the growing recognition and potential of technology dedicated to women’s health.

Founded in 2015, Flo Health has swiftly risen to prominence with its innovative mobile application designed to track menstrual cycles, ovulation, and overall reproductive health. The app has garnered over 230 million downloads globally, making it a crucial tool for millions of women seeking to manage their health more effectively. This investment from General Atlantic is poised to propel Flo Health into its next phase of growth, enabling it to expand its product offerings and enhance its technological capabilities.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

General Atlantic’s decision to invest such a substantial sum is indicative of the broader trends within the femtech sector. The femtech market, which includes a range of products and services aimed at improving women’s health, is projected to grow exponentially over the next decade. The increasing awareness of women’s health issues, coupled with advancements in technology, has created a fertile ground for innovation and investment. By backing Flo Health, General Atlantic is not only supporting a single company but also signalling confidence in the sector’s future.

Yaroslava Goncharova, CEO of Flo Health, expressed enthusiasm about the partnership with General Atlantic, stating, “This investment will allow us to accelerate our mission of improving the health and wellbeing of women globally. We are excited to leverage General Atlantic’s expertise and resources to further enhance our product and reach more women around the world.”

Flo Health’s success is rooted in its user-centric approach, leveraging data science and artificial intelligence to provide personalised health insights. The app’s features include symptom tracking, health predictions, and educational content, all designed to empower women with knowledge about their bodies. With the new funding, Flo Health plans to deepen its AI capabilities, enhance its user experience, and expand its educational content, ensuring it remains at the forefront of the femtech industry.

General Atlantic, known for its strategic investments in technology and healthcare, sees Flo Health as a strategic addition to its portfolio. Sandeep Naik, Managing Director and Head of India & Southeast Asia at General Atlantic, highlighted the potential for growth in the femtech space. “Flo Health is at the intersection of healthcare and technology, addressing a significant market need with its innovative solutions. We believe in the company’s vision and are committed to supporting its growth trajectory.”

The $200 million investment also reflects a broader shift in the investment landscape, where gender-specific health solutions are gaining traction among investors. The femtech sector, which has historically been underfunded, is now witnessing increased interest and funding, signalling a positive change in how women’s health is valued and supported.

Flo Health’s journey from a startup to a leading player in femtech exemplifies the transformative potential of technology in healthcare. With General Atlantic’s backing, the company is well-positioned to continue its upward trajectory, driving innovation and improving health outcomes for women worldwide. As Flo Health embarks on this new chapter, the femtech industry will undoubtedly be watching closely, anticipating the strides the company will make in advancing women’s health.

The Future Forbes Realty Global Properties

Citigroup Raises Eurobank Target Price Following Strong Q1 Results

Revised Target Price Reflects Strengthened Outlook

Citigroup raised its target price for Eurobank to €5.00 from €4.70 while maintaining a buy recommendation following the bank’s first-quarter results and upgraded medium-term profitability outlook. Based on Eurobank’s reference share price of €3.72 on May 15, 2026, Citigroup’s revised target implies upside potential of 34.4%, rising to 38.5% when the estimated dividend yield of 4.1% is included.

Enhanced Earnings And Comprehensive Forecasts

The upgraded analysis from Citigroup, as reported by Newmoney, points to bolstered momentum in net interest income and fee generation. The investment bank has revised its normalized earnings per share forecasts upward: 4% for 2026, 9% for 2027, and 14% for 2028, primarily driven by higher expected net interest income and increased commissions.

Scenario Analysis Offers Range Of Outcomes

Citigroup’s bullish scenario values Eurobank shares at €6.10, implying potential upside of 64%. Its downside scenario projects a share price of €3.55, approximately 4.6% below the May 15 reference level. The optimistic case assumes a return on tangible equity one percentage point higher, alongside a 100 basis point reduction in the cost of equity. Meanwhile, the negative scenario assumes a 1.5 percentage point lower return combined with a 200 basis point increase in the cost of equity.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Solid Q1 Results Support Growth Targets

Eurobank reported normalized net profits of €351 million during the first quarter, broadly in line with market expectations. Reported net profit reached €331 million after a €35 million expense linked to a voluntary exit programme involving around 200 employees. The programme is expected to generate annual savings of approximately €14 million. Net interest income increased 3% quarter-on-quarter, exceeding consensus forecasts by 2% and supporting expectations that the bank could surpass its €2.6 billion target for 2026.

Looking Ahead: Ambitious Growth And Profitable Outlook

Organic loan growth reached €1.1 billion during the quarter, supporting management’s target for €3.8 billion in annual organic credit expansion. Fee income also rose 20% year-on-year, outperforming forecasts by 4%. Citigroup projects Eurobank’s net profit will reach €1.45 billion in 2026, with earnings per share of €0.40 and a dividend of €0.20 per share.

By 2028, the bank forecasts net profit of €1.76 billion alongside further improvement in profitability metrics and dividend yield. The revised projections reinforce expectations that Eurobank will continue benefiting from stronger lending activity, resilient fee income and improving operational efficiency.